Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis.

Suppr

超能文献

作者信息

Aberg L, Talling M, Härkönen T, Lönnqvist T, Knip M, Alen R, Rantala H, Tyynelä J

机构信息

Pediatric Neurology, University of Helsinki, Helsinki, Finland.

出版信息

Neurology. 2008 Apr 1;70(14):1218-20. doi: 10.1212/01.wnl.0000307753.88839.29.

DOI:10.1212/01.wnl.0000307753.88839.29

PMID:18378887

Abstract

摘要

相似文献

Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis.

Neurology. 2008 Apr 1;70(14):1218-20. doi: 10.1212/01.wnl.0000307753.88839.29.

Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis.

Neuropathol Appl Neurobiol. 2006 Oct;32(5):469-82. doi: 10.1111/j.1365-2990.2006.00738.x.

Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes.

Ann Neurol. 2008 Jan;63(1):127-8. doi: 10.1002/ana.21011.

An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses.

Neurology. 2002 Dec 10;59(11):1816-7. doi: 10.1212/01.wnl.0000041913.97883.8b.

IgG entry and deposition are components of the neuroimmune response in Batten disease.

Neurobiol Dis. 2007 Feb;25(2):239-51. doi: 10.1016/j.nbd.2006.09.005. Epub 2006 Oct 27.

Altered elemental profiles in neuronal ceroid lipofuscinosis.

J Trace Elem Electrolytes Health Dis. 1990 Sep;4(3):139-42.

Antibody-phenotype correlation in stiff-person syndrome.

Neurology. 2008 Dec 9;71(24):1938-9. doi: 10.1212/01.wnl.0000334364.29899.db. Epub 2008 Oct 29.

[Ceroid lipofuscinosis].

Tijdschr Kindergeneeskd. 1989 Oct;57(5):177-81.

Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.

Pediatr Neurol. 2009 Oct;41(4):297-300. doi: 10.1016/j.pediatrneurol.2009.04.022.

Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders.

Neurology. 2004 Dec 14;63(11):2001-5. doi: 10.1212/01.wnl.0000145836.72059.3b.

引用本文的文献

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Curr Res Pharmacol Drug Discov. 2021 Apr 8;2:100022. doi: 10.1016/j.crphar.2021.100022. eCollection 2021.

Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Expert Opin Orphan Drugs. 2019;7(11):473-500. doi: 10.1080/21678707.2019.1684258. Epub 2019 Nov 27.

Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Drugs. 2021 Jan;81(1):101-123. doi: 10.1007/s40265-020-01440-7.

Inherited disorders of lysosomal membrane transporters.

Biochim Biophys Acta Biomembr. 2020 Dec 1;1862(12):183336. doi: 10.1016/j.bbamem.2020.183336. Epub 2020 May 8.

Therapeutic landscape for Batten disease: current treatments and future prospects.

Nat Rev Neurol. 2019 Mar;15(3):161-178. doi: 10.1038/s41582-019-0138-8.

Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights.

Degener Neurol Neuromuscul Dis. 2016 Aug 1;6:73-83. doi: 10.2147/DNND.S111967. eCollection 2016.

Clinical trials in rare disease: challenges and opportunities.

J Child Neurol. 2013 Sep;28(9):1142-50. doi: 10.1177/0883073813495959.

Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Curr Pharm Biotechnol. 2011 Jun;12(6):867-83. doi: 10.2174/138920111795542633.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis.

Neurology. 2008 Apr 1;70(14):1218-20. doi: 10.1212/01.wnl.0000307753.88839.29.

Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis.

Neuropathol Appl Neurobiol. 2006 Oct;32(5):469-82. doi: 10.1111/j.1365-2990.2006.00738.x.

Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes.

Ann Neurol. 2008 Jan;63(1):127-8. doi: 10.1002/ana.21011.

An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses.

Neurology. 2002 Dec 10;59(11):1816-7. doi: 10.1212/01.wnl.0000041913.97883.8b.

IgG entry and deposition are components of the neuroimmune response in Batten disease.

Neurobiol Dis. 2007 Feb;25(2):239-51. doi: 10.1016/j.nbd.2006.09.005. Epub 2006 Oct 27.

Altered elemental profiles in neuronal ceroid lipofuscinosis.

J Trace Elem Electrolytes Health Dis. 1990 Sep;4(3):139-42.

Antibody-phenotype correlation in stiff-person syndrome.

Neurology. 2008 Dec 9;71(24):1938-9. doi: 10.1212/01.wnl.0000334364.29899.db. Epub 2008 Oct 29.

[Ceroid lipofuscinosis].

Tijdschr Kindergeneeskd. 1989 Oct;57(5):177-81.

Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.

Pediatr Neurol. 2009 Oct;41(4):297-300. doi: 10.1016/j.pediatrneurol.2009.04.022.

Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders.

Neurology. 2004 Dec 14;63(11):2001-5. doi: 10.1212/01.wnl.0000145836.72059.3b.

引用本文的文献

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Curr Res Pharmacol Drug Discov. 2021 Apr 8;2:100022. doi: 10.1016/j.crphar.2021.100022. eCollection 2021.

Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Expert Opin Orphan Drugs. 2019;7(11):473-500. doi: 10.1080/21678707.2019.1684258. Epub 2019 Nov 27.

Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Drugs. 2021 Jan;81(1):101-123. doi: 10.1007/s40265-020-01440-7.

Inherited disorders of lysosomal membrane transporters.

Biochim Biophys Acta Biomembr. 2020 Dec 1;1862(12):183336. doi: 10.1016/j.bbamem.2020.183336. Epub 2020 May 8.

Therapeutic landscape for Batten disease: current treatments and future prospects.

Nat Rev Neurol. 2019 Mar;15(3):161-178. doi: 10.1038/s41582-019-0138-8.

Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights.

Degener Neurol Neuromuscul Dis. 2016 Aug 1;6:73-83. doi: 10.2147/DNND.S111967. eCollection 2016.

Clinical trials in rare disease: challenges and opportunities.

J Child Neurol. 2013 Sep;28(9):1142-50. doi: 10.1177/0883073813495959.

Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Curr Pharm Biotechnol. 2011 Jun;12(6):867-83. doi: 10.2174/138920111795542633.